Preparation of highly pure toxin fragments
US7193066B1 · kind B1 · utility
11Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2000 |
| Grant date | Mar 20, 2007 |
| Priority date | — |
| Expiry date | Dec 7, 2021 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/811
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Toxin derivatives are prepared by proteolytic treatment of holotoxin, and their toxicity is reduced by contacting the preparation with a ligand, which can be a metal or an antibody or another ligand. This ligand selectively binds to the toxin but not to the toxin derivative. Removing the ligand and toxin bound to the ligand further reduces toxicity. A second ligand is used to remove conjugates of the toxin and the first ligand. Compositions contain the purified derivative, optionally plus the toxin and the ligand.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.